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Abstract 
Purpose: To investigate the proliferative activity and neuroprotective effect of a newly identified 
ligustrazine derivative (4-((3,5,6-trimethylpyrazine-2-yl)methoxyl)-3-methox-ybenzoic acid-3,5,6-
trimethylpyrazin- 2-methyl ester, T-VA) and the possible mechanism related to vascular endothelial 
growth factor (VEGF) in cerebral ischemic injury. 
Methods: The pharmacological activity of T-VA was evaluated using MTT ((3-(4,5-dimethylthiazolyl2-
yl)-2,5-diphenyltetrazolium bromide)) assay, while cellular morphology was observed with hematoxylin 
and eosin (HE) staining. Chick chorioallantoic membrane (CAM) model, immuno-histochemical analysis, 
and enzyme-linked immunosorbent assay (ELISA) were used to determine the expression of VEGF. 
Middle cerebral artery occlusion (MCAO) model was used to investigate both VEGF expression and the 
survival rate after treatment with T-VA. 
Results: T-VA promoted neuron activity, and the doses of 15 and 30 μM showed more significant effect 
(p < 0.05). The viability of PC12 cells increased significantly in T-VA (30 and 60 μM) groups (p < 0.05) 
and increased in a dose-dependent manner. Immunohistochemical analysis showed stimulated VEGF 
expression, and CAM model results showed that T-VA (20 mg/egg) significantly promoted micro-
angiogenesis (p < 0.01). Moreover, in MCAO model, the survival rate of T-VA (60 mg/kg) group reached 
86.7 % while for the ischemia group it was 60.0 %. In addition, ELISA results showed that T-VA 
promoted the expression of VEGF (p < 0.05). 
Conclusion: These findings indicate that T-VA helps to prevent ischemic injury by increasing VEGF 
expression. 
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Ischemic stroke has attracted attention in 
domestic and international research, and several 
reviews have recently been published about the 
effect and potential benefits of traditional 
Chinese medicine in the treatment of cerebral 
ischemic injury [1]. It has been suggested that 
some herbal medicines, or their products, may 
have the functions of improving microcirculation 
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in the brain, protecting against ischemic injury, 
improving cerebrovascular properties, and 
inhibiting neuron apoptosis [2-4]. The lack of 
effective and widely applicable pharmacological 
treatments for ischemic stroke patients may 
explain the growing interest in discovering drugs 
derived from traditional medicines [5]. 
 
As one of the major effective ingredients of 
Rhizoma Chuanxiong ligustrazine (2,3,5,6-
tetramethylpyrazine, TMP) has been widely used 
in the treatment of ischemic stroke and 
cerebrovascular disease in China for many years 
[6] Previous studies have shown various 
pharmacological activities of TMP, such as anti-
myocardial ischemia, anti-cerebral ischemia, 
inhibiting platelet aggregation, protecting 
vascular endothelial, etc [7-11]. To further 
improve the neuroprotective property of TMP, we 
decided to undertake a study of a novel series of 
TMP derivatives based on the principles of 
hybridization and prodrug design in medicinal 
chemistry and acquired compounds with 
pharmacologically additive or synergetic e ects 
[12-14]. It has been demonstrated that T-VA ((4-
((3,5,6-trimethylpyrazine-2-yl)methoxyl)-3-
methoxybenzoic acid-3,5,6-trimethylpyrazin- 2-
methyl ester; see Results, Figure 1A) has a 
promising protective effect against CoCl2-
induced neurotoxicity in differentiated PC12 cells 
(EC50 = 4.249 µM) [15] and that the plasma 
concentration of T-VA reaches peak levels 
between 4 and 6 h post-intragastric 
administration [16]. Interestingly, some studies 
show that congener structures of T-VA possess 
protective effects on damaged vascular 
endothelial cells, such as ECV-304 cells, human 
umbilical vein endothelial cells (HUVECs) and 
Hy-926 cells [17-19]. Moreover, ligustrazine 
derivatives showed good antiplatelet aggregation 
activity [19]. 
 
Based on the aforementioned evidence, we 
reasoned that the neuroprotective effect of T-VA 
might be associated with its thrombolytic and 
vascular biological properties. Vascular 
endothelial growth factor (VEGF), an angiogenic 
protein, is able to enhance survival ability of 
endothelial cells and has a role in thrombus 
resolution that was helpful in the treatment of 
cerebral ischemia [20,21]. This potential 
therapeutic value and neuroprotective effect in 
ischemia might be mediated by VEGF itself or by 
a signal transduction pathway activated by VEGF 
[22]. VEGF was shown to attenuate acute 
neuronal death and play a neuroprotective role 
under oxygen-glucose deprivation conditions 
through VEGFR-2 [23]. Moreover, when VEGF 
was used to treat focal cerebral ischemia in rats, 
the infarct volume was reduced and neurological 
functions were improved [24]. Therefore, our aim 
was to investigate the proliferative activity and 
neuroprotective effect of T-VA and the possible 







Rats (female rats pregnant for 16-18 days and 
male SD rats weighing 280-300 g) were 
purchased from Beijing Vital River Laboratory 
Animal Technology Company Limited (Beijing, 
China) and kept under standard laboratory 
conditions (tap water, constant room 
temperature, 22 °C). All animal protocols were 
approved by the Ethics Committee of Beijing 
University of Chinese Medicine in accordance 
with the National Institutes of Health guidelines 
(Contract 2012-0036, June 2012). All efforts 
were made to minimize animal suffering and to 
reduce the number of animals used. PC12 cell 
line was purchased from the Institute of Materia 
Medica of the Chinese Academy of Medical 
Science. Fertilized White Leghorn chicken eggs 
were provided by Chinese Academy of 
Agricultural Sciences. 
 
Animals, neurons culture and drugs 
 
Fetal rats were taken from pregnant rats and 
washed twice with 4 °C phosphate buffered 
saline (PBS). After stripping the meninges and 
vessels, the brains of fetal rats were cut into 1 
mm3 cubes. All steps were conducted on ice. 
Neurons were isolated by 0.1 % trypsin digestion 
for 10 min in a 37 °C incubator and fixed with 
Dulbecco’s modified eagle  medium supple-
mented with 10 %(v/v) fetal bovine serum and 
100 U/mL penicillin-streptomycin (Thermo 
Technologies, New York, NY, USA) [25,26]. 
Then neurons were seeded onto poly-L-lysine-
coated 96-well culture plates at 8 × 104 cells/well, 
and the plates were incubated at 37 °C in a 
humidified atmosphere of 5 % CO2 for 48 h. 
Subsequently, the neurons were treated with 
different doses of T-VA (60, 30, and 15 μM) and 
nimodipine (NMDP) for 24 h. 
 
PC12 cell culture and drugs 
 
PC12 cells were cultured in RPMI 1640 medium 
supplemented with 5 % (v/v) fetal bovine serum, 
10 % (v/v) horse serum and 100 U/mL penicillin-
streptomycin (Thermo Technologies, New York, 
NY, USA) at 37 °C in a humidified atmosphere of 
5 % CO2. When cells achieved the desired 
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density of > 80 % confluency, the original 
medium was removed and cells were cultured 
with a serum-free medium for 12-14 h. Then the 
cells were suspended in the RPMI 1640 medium 
supplemented with 10 % (v/v) fetal bovine serum, 
and seeded into poly-L-lysine-coated 96-well 
culture plates at 7 × 104 cells/well, differentiated 
by treated with nerve growth factor (NGF; 50 
ng/mL) for 48 h [2]. Subsequently, the 
differentiated PC12 cells were treated for 36 h 
with various concentrations (60, 30, 15 μM) of T-
VA or RPMI 1640 medium supplemented with 10 
% (v/v) fetal bovine serum. T-VA was dissolved 
in dimethyl sulfoxide (DMSO). The final 
concentration of DMSO was < 0.1 % (v/v). 
 
MTT (3-(4,5-dimethylthiazolyl2-yl)-2,5-
diphenyltetrazolium bromide) assay 
 
After MTT solution (20 μL, 5 mg/mL) was added 
to each well, the plate was incubated for an 
additional 4 h at 37 °C. The supernatant was 
removed carefully by pipetting from wells without 
disturbing the attached cells. Formazan crystals 
were solubilized by adding 150 μL of DMSO to 
each well, and then the plate was shaken for 15 
min [2]. The absorbance of neurons at 540 nm 
and PC12 cells at 490 nm were measured with a 
Bio-Rad 550 spectrophotometer (Bio-rad, 
California, CA, USA).  
 
Hematoxylin and eosin (HE) staining method 
 
After pretreatment with the serum-free medium 
for 12-14 h, cells were seeded at a concentration 
of 7 × 104 cell/mL on a poly-L-lysine-coated 
sterile cover slip in 24-well tissue culture plates, 
and differentiated by treatment with NGF (50 
ng/mL) for 48 h. The differentiated PC12 cells 
were pretreated with T-VA for 36 h at the 
optimum concentration (60 μM), which was 
selected by MTT assay. Cover slips were 
washed twice with PBS, removed and treated 
with acetone for 10 min at -20 °C. Then cells 
were washed with PBS and stained with 
hematoxylin for 3 min. The stained nuclei were 
rinsed with running water for 1 h followed by 
eosin staining for another 2 min. Finally, stained 
sections were dehydrated using gradient ethanol 
and cleared in xylene [2,27]. The cellular 
morphology was photographed by light 
microscopy (Nikon, Kobe, Japan). 
 
Immunohistochemical analysis of VEGF 
 
Our previous study demonstrated that T-VA 
protect CoCl2-induced neurotoxicity in 
differentiated PC12 cells [2], so all 
measurements were performed after PC12 cells 
were induced by CoCl2 (dissolved in RPMI 1640 
medium, 200 mM) for 12 h. Cells in the NGF 
group were not treated with T-VA and CoCl2. 
Briefly, after being washed three times with PBS, 
PC12 cells were fixed in acetone for 10 min at -
20 °C. After being blocked in 3 % H2O2-CH3OH 
for 30 min at 37 °C, the cells were incubated with 
VEGF antibodies overnight at 4 °C. Cells were 
then incubated in horseradish peroxidase-
conjugated AffiniPure goat anti-rabbit 
immunoglobulin G (IgG) diluted to 1:250 in PBS 
for 30 min at 37 °C, followed by streptavidin-
biotin complex (SABC) for 30 min at 37 °C. 3, 3-
Diaminobenzidine (DAB) was used as a 
chromogen for 10 min. PBS was used between 
each step to wash the cover slips. Finally, PC12 
cells were stained with hematoxylin for 30-60 s 
and washed with running water for 1 h. Stained 
sections were dehydrated using gradient ethanol 
and cleared in xylene. The expression of VEGF 
was observed and photographed under a 
microscope [28]. 
 
Chick chorioallantoic membrane (CAM) 
model 
 
The eggs were placed in an incubator 
immediately after embryogenesis started and 
were kept under constant humidity of 65 % at 37 
°C. On the 7th day, a square window was 
opened on the shell and physiological saline (0.1 
mL) was injected in to detach the shell 
membrane. T-VA was carried by gelatin sponges 
and implanted at 10 and 20 μg/egg. The control 
group was treated with physiological saline. The 
windows were sealed with medical adhesive 
tape. The aforementioned treatment steps were 
all performed under sterile conditions. On the 
11th day, the tape was removed and the entire 
CAM was detached after tissue fixation with 
methanol/acetone (1:1, v/v). Then, computer-
assisted image tracking was used to obtain 
absolute values for the number of microvessels 
that were 1-100 μm in diameter [15]. The model 
was established according to previously 
published method [29] and our previous studies 
[30]. 
 
Middle cerebral artery occlusion (MCAO) 
model 
 
Transient MCAO was conducted in male rats 
according to the previously published methods 
[31,32]. There were 15 rats in each of the MCAO 
and sham-operated groups. Briefly, male rats 
were anesthetized with 10 % chloral hydrate (350 
mg/kg), and the right common carotid artery and 
external carotid arteries were isolated and 
ligated. A nylon suture (diameter 0.25 mm) was 
advanced from the common carotid artery to the 
internal carotid artery for a distance of 
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approximately 18-20 mm from the external-
internal carotid artery. The blocking of the middle 
cerebral artery induced cerebral ischemia. Then 
the muscle and skin were sutured with 4-0 nylon. 
Penicillin (4 million units/mL) was given to the 
rats for 3 days following the operation. In sham-
operated rats, internal and external carotid 
arteries were also exposed and separated. When 
the rats recovered consciousness, 6 h after the 
operation, scores were graded as follows: 
according to Bederson’s description [33]: 0, no 
deficit; 1, failure to fully extend left forepaw; 2, 
circling to the left; 3, falling to the left; 4, no 
spontaneous walking with a depressed level of 
consciousness. Rats with scores from 1 to 3 
were selected for further testing and were divided 
randomly to the ischemia group, T-VA group 
(120 mg/kg and 60 mg/kg), and NMDP group. 
The rats were treated with T-VA by intragastric 
administration (1 mL/100g) once a day until the 
10th day. The sham and model groups were 
treated with isovolumetric 0.5 % sodium 
carboxymethyl cellulose (CMC-Na). 
 
Enzyme-linked immunosorbent assay (ELISA) 
for VEGF detection 
 
The level of VEGF in serum was measured with 
sandwich ELISA kits. Optical densities were 





Statistical comparisons between groups were 
made by one-way ANOVA followed by Student’s 
t-test using the SPSS version 20. Results were 




Effect of T-VA on neuron activity 
 
As shown in Figure 1B, the control group was set 
as 100 % neuronal activity based on the optical 
density (OD) values of the MTT assay. T-VA 
promoted neuron activity in all treatment groups, 
but the doses of 15 and 30 μM showed more 
significant effect (p < 0.05) than the high dose of 
60 μM. The activity of neurons in NMDP group 
also increased compared with the control group. 
Under optical microscopy, neurons in control 
group exhibited pyramidal cell body with fine 
dendritic networks (Figure 1C). More neurons are 
evident in the NMDP group compared with 
control group (Figure 1D). In addition, the 
number of neurons and the dendritic networks 
increased with various concentrations of T-VA. 
Notably, the T-VA doses of 15 and 30 μM 
induced better neuron growth than the high dose 
(60 μM) group (Figures 1E-1G). 
 
Effect of T-VA on differentiated PC12 cells 
 
The NGF group was set as 100 % activity of 
PC12 cells. Results of the MTT assay showed 
that T-VA at 15, 30, and 60 µM increased cell 
viability to 110.14 %, 128.99 % and 144.93 %, 
respectively in a dose-dependent manner. 
Observation of morphologic changes of PC12 
cells revealed that undifferentiated PC12 cells 
proliferated to form clone-like cell clusters without 
neural characteristics (Figure 2B), that PC12 
cells differentiated by NGF had round cell bodies 
with fine dendritic networks and intact and clear 
cell edges (Figure 2C), and that cells in NMDP 
group had long synapse (Figure 2D). PC12 cells 
treated with T-VA had the longest synapse of all 
the groups and an obvious increase in the 
amount of neurite-bearing cells compared with 
the control group (Figure 2E). 
 
Expression of VEGF in differentiated PC12 
cells 
 
The immunohistochemical results of VEGF are 
represented in Figure 3. The CoCl2 group 
showed weak expression of VEGF (Figure 3B). 
The brown staining of the NGF and NMDP 
groups was obviously increased (Figures 3A and 
3C). Moreover, the T-VA group (60 μM) 
displayed significant expression of VEGF 
compared with the CoCl2 group (Figure 3D). 
 
Microvascular proliferation of T-VA on CAM 
 
T-VA had microvascular proliferation effect on 
CAM. When the dose of T-VA was 10 μg/egg, 
the impact of promoting microvascular 
proliferation was not very obvious (Figures 4A 
and 4C). However, when the dose was increased 
to 20 μg/egg, microvascular proliferation 
increased significantly compared with control 
group (p < 0.01) (Figure 4A). As exhibited in 
Figure 4D, we found that the amount of 
microvascular distinctly increased compared with 
the control group. 
 
Effect of T-VA on survival rate and VEGF 
expression in rats with MCAO 
 
Both survival rate and VEGF expression were 
markedly reduced in MCAO rats with ischemia 
compared with survival rate and VEGF 
expression in sham-operated rats, which were 
set as 100 % (Figures 5A and 5B). Survival rates 
in MCAO rats after treatment with 120 and 60 
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mg/kg of T-VA were increased by 6.7 and 26.7 
%, respectively, compared with the survival rate 
in the untreated MCAO ischemia group. The 
survival rate in the MCAO rats after treatment 
with NMDP was also increased (by 20 %) 
compared with the survival rate in the untreated 
MCAO ischemia group. The areas of VEGF 
expression, determined by both ELISA and 
immunohistochemistry (IHC), were significantly 
decreased in the untreated MCAO ischemia 
group compared with VEGF expression in the 
sham-operated group (Figure 5B).  
 
The results of immunohistochemistry (IHC) are in 
agreement with the ELISA results. ELISA results 
revealed that the VEGF expression increased 
significantly in the T-VA (60 mg/kg) group (Figure 
5B) and IHC results revealed a significant 
increase in VEGF expression in both T-VA 
treatment groups (60 and 120 mg/kg) compared 
with that in the untreated MCAO ischemic group. 
The contents of VEGF in the 60 and 120 mg/kg 
T-VA treatment groups were 25.67 and 22.86 
ng/mg protein, respectively, which corresponds 
to a 26.26 % and 16.28 % increase, respectively, 
compared with the VEGF content in the 
untreated MCAO ischemia group (18.28 ng/mg 
protein). NMDP treatment did not significantly 





Figure 1: (A) Structure of T-VA. (B) Activity of neurons treated with T-VA. * p < 0.05, compared with control 
group. (C) The morphology of neurons in control group. (D) The morphology of neurons treated with NMDP. (E-
G) The morphology of neurons treated with T-VA (15, 30, and 60 µM). (×20) 
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Figure 2: Effect of T-VA on PC12 cells. (A) Activity of differentiated PC12 cells. * p < 0.05, compared with control 
group. ** p < 0.01, compared with control group. (B) Undifferentiated PC12 cells (C) PC12 cells differentiated by 





Figure 3: Expression of VEGF in differentiated PC12 cells. (A) PC12 cells differentiated by NGF. (B) 
Differentiated PC12 cells exposed to CoCl2 insult. (C) Differentiated PC12 cells pre-incubated with NMDP and 
then exposed to CoCl2 insult. (D) Differentiated PC12 cells pre-incubated with T-VA (60μM) and then exposed to 
CoCl2 insult. (×400) 
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Figure 4: Microvascular proliferation of T-VA on CAM (n = 7). (A) The number of microvasessels on CAM model. 





Figure 5: (A) Survival rate of rats with MCAO. (Survival rate = survival rats after 10 days of treatment/original 15 
rats of each group); (B) Effect of T-VA on VEGF in rats with MCAO. * p < 0.05, compared with untreated MCAO 
ischemia group. Results are shown for ELISA (left, gray bars) and IHC (right, hashed bars) 
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It was previously reported that T-VA has a 
protective effect against injured PC12 cells (EC50 
= 4.249 µM), whereas the congener structures of 
T-VA possess protective effects against 
damaged vascular endothelial cells [17-19]. In 
the present study, T-VA displayed the ability to 
promote the activities of neurons and PC12 cells 
(p < 0.05), and histopathological analyses 
coincided with the cell viability detected by the 
MTT assay. Overall, T-VA exhibited a positive 
effect on neurons in this study. 
 
VEGF, a major mediator of angiogenesis, plays 
an important role in recovery of ischemic injury 
and serves as a useful positive control [34,35]. 
Our present study showed that T-VA exhibited 
the ability to stimulate VEGF expression in PC12 
cells. Further study using CAM model showed 
that T-VA significantly promoted micro-
angiogenesis (p < 0.01). These findings suggest 
that there might be a correlation between VEGF 
expression and cell viability. When the rats were 
treated with T-VA, VEGF up-regulated 
dramatically, thereby preventing MCAO rats from 
ischemic injury. Additionally, this study indicates 
that the survival rate of MCAO rats after 
treatment with T-VA was 26.67 % higher than 
that in the ischemia group, suggesting an 
effective approach against ischemic injury.  
 
Obviously, it is of vital importance to increase the 
survival rate for the patients. All the findings in 
present study suggest that the neuroprotective 
effect of T-VA may be related to an increase of 
VEGF expression, laying the foundation for 
further research of the mechanism. This study 
also indicates the feasibility of discovering more 
efficient compounds from traditional Chinese 




T-VA promotes the activities of neurons and 
differentiated PC12 cells and increases the 
expression of VEGF both in vitro and in vivo in 
rats. Therefore, T-VA may be a potential 
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